- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
OKRA.ai Extends Collaboration with Bristol Myers Squibb
OKRA.ai, a provider of Artificial Intelligence (AI) driven analytics for global life sciences, today announced that it is extending its collaboration with Bristol Myers Squibb to leverage OKRA’s AI Technology to support future customer engagement. This collaboration, which started in the UK in 2018 has proven to be very successful in bringing together multiple data sources and generating intelligent insights for commercial teams whilst delivering unparalleled levels of automation for the company. In 2021 OKRA.ai and Bristol Myers Squibb expanded use of the system to new markets and will continue to work together and explore further expansion opportunities in 2022.
Read more about the collaboration here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
